Ivette Alarcon
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Criteria for Hidradenitis Suppurativa Competence Centers.
Journal: Dermatology and therapy
Published: March 20, 2026
Exploring the Impact of Fatigue and Sleep Disturbance in Hidradenitis Suppurativa: Perspectives from Patients and Healthcare Professionals.
Journal: Acta dermato-venereologica
Published: November 12, 2025
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt Treatment.
Journal: American journal of clinical dermatology
Published: September 26, 2025
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.
Journal: International journal of dermatology
Published: June 20, 2025
Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.
Journal: Dermatology and therapy
Published: March 25, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.
Journal: Dermatology and therapy
Published: January 27, 2025
The role of surgery in hidradenitis suppurativa: Expert-based holistic approaches.
Journal: Clinical and experimental dermatology
Published: October 30, 2024
The role of surgery in hidradenitis suppurativa: expert-based holistic approaches.
Journal: Clinical and experimental dermatology
Published: October 30, 2024
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.
Journal: The British journal of dermatology
Published: April 25, 2024
Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.
Journal: Frontiers in medicine
Published: March 19, 2024
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Journal: The British journal of dermatology
Published: December 07, 2023
Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Journal: The Journal of rheumatology
Published: October 06, 2023
Last Updated: 09/26/2026